Bayer Signs a Research and License Agreement with Curadev to Develop Novel STING Antagonists Across Multiple Indications

Bayer Signs a Research and License Agreement with Curadev to Develop Novel STING Antagonists Across Multiple Indications

Shots:

  • Curadev to receive upfront, research funding, pre-clinical, clinical and commercial milestones of $266.9M along with royalties on sales. Bayer to gain exclusive access to novel molecules from Curadev, designed to inhibit the STING pathway
  • The alliance focusses to discover new therapies targeting lung diseases, CV diseases and other inflammatory diseases. The collaboration will optimize and advance the novel molecules generated during the collaboration into clinical development
  • STING antagonists offer the potential for new treatments as STING plays a role in activating the innate immune system in auto-inflammatory diseases

Click here ­to­ read full press release/ article | Ref: Bayer | Image: Latifundist